Strategy & Portfolio
Define Where to Compete. Design How to Win.
From long-range corporate strategy to Africa-specific go-to-market architecture, we help leadership teams make the decisions that shape the next five years — with the rigour and regional depth those decisions require.
Strategy in African pharma that is not grounded in deep market knowledge is not strategy — it is aspiration.
The strategic questions facing pharma companies in Africa and the Middle East are distinct in important ways from those that dominate headquarters planning cycles. Which markets to prioritise among fifty-four diverse regulatory environments? How to sequence geographic expansion when distribution infrastructure, pricing dynamics, and health authority capacity vary enormously from country to country? How to allocate portfolio resources when local competitive dynamics bear no resemblance to global market share data?
These are not questions that generic strategy frameworks answer well. They require someone who understands the region, has seen what works and what fails, and can translate that experience into a strategic architecture that your organisation can actually execute.
Helix Bridge works with pharma leadership teams to answer the questions that matter: where to compete, how to sequence market entry, how to configure the portfolio for the African opportunity, and how to build a go-to-market model that closes the gap between global strategy and local performance. We bring the Africa-native perspective that most global consulting firms genuinely cannot offer — because they have not been here long enough, at the right level, in the markets that count.
Our strategy work is not theoretical. Every recommendation is tested against the market realities and organisational constraints that determine whether it can be executed. And because we stay close to our clients through implementation, we know from direct experience which strategic choices hold up under real conditions.
What We Deliver
- Corporate and franchise strategy development for MEA portfolios, including market prioritisation, resource allocation, and three-to-five-year commercial roadmaps
- Africa go-to-market model design: market entry strategy, commercial channel architecture, and phased expansion planning across Sub-Saharan Africa, North Africa, and the Levant
- Portfolio analysis and lifecycle management strategy, including geographic indication expansion, biosimilar positioning, and product rationalization
- Competitive landscape assessments and opportunity sizing for African and Middle Eastern markets
- Strategic option evaluation and scenario modelling for market entry, partnership, or distribution strategy decisions
- Business case development for new market investment, including financial modelling and sensitivity analysis calibrated to regional market dynamics
- Strategic alignment workshops with leadership teams, bridging the gap between headquarters strategy and MEA commercial realities
Who This Is For
Developing multi-year commercial strategies and making the portfolio allocation decisions that will define your next planning cycle.
Building the Africa business case, evaluating market entry options, or designing a go-to-market model that reflects how these markets actually work.
Assessing the African opportunity for the first time and needing a grounded, market-specific strategy rather than a global template applied to new geography.
Evaluating healthcare assets in Africa and needing genuine market intelligence to inform investment thesis and commercial due diligence.
Tell us about your strategic challenge — we'll tell you how we can help build the foundation for commercial growth in Africa and the Middle East.
Discuss Your Strategy Needs →